|
End-of-day quote
Taipei Exchange
30/10/2026
|
5-day change | 1st Jan Change | ||
| 159.00 TWD | -1.55% |
|
-2.15% | +300.50% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 132B 4.04B 3.62B 3.33B 3.02B 5.64B 384B 5.74B 39.69B 15.93B 202B 15.16B 14.84B 636B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 116B 3.54B 3.17B 2.92B 2.64B 4.94B 336B 5.03B 34.8B 13.97B 177B 13.29B 13.01B 558B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -1.55% | ||
| 1 week | -2.15% | ||
| 1 month | -16.54% | ||
| 3 months | +133.48% | ||
| 6 months | +289.23% | ||
| Current year | +300.50% |
| 1 week | 153 |  | 166.5 |
| 1 month | 149 | | 191 |
| Current year | 33.1 | | 207 |
| 1 year | 24.75 | | 207 |
| 3 years | 7 | | 207 |
| 5 years | 7 | | 207 |
| 10 years | 2.7 | | 207 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 31/05/2016 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 24/07/2022 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 31/07/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 12/10/2016 |
Cheng Chi Wang
BRD | Director/Board Member | - | 26/06/2024 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 26/09/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.55% | -2.15% | +495.51% | +1,288.65% | 4.04B | |
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | |
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | |
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | |
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | |
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | |
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | |
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | |
| Average | +1.72% | +4.99% | +91.47% | +204.97% | 426.6B | |
| Weighted average by Cap. | +2.00% | +6.49% | +50.93% | +101.56% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -22.81M -20.43M -18.79M -17.03M -31.83M -2.17B -32.42M -224M -89.95M -1.14B -85.6M -83.78M -3.59B | -1.36B -41.77M -37.41M -34.41M -31.18M -58.28M -3.97B -59.37M -410M -165M -2.09B -157M -153M -6.58B |
| Net Debt | -5.17B -159M -142M -131M -118M -221M -15.06B -225M -1.56B -625M -7.92B -595M -582M -24.98B | -16.27B -499M -447M -411M -372M -696M -47.34B -709M -4.9B -1.97B -24.9B -1.87B -1.83B -78.54B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | NT$159.00 | -1.55% | 3,697,525 |
| 29/10/26 | NT$161.50 | +0.62% | 3,713,771 |
| 28/10/26 | NT$160.50 | +2.56% | 2,840,771 |
| 27/10/26 | NT$156.50 | -3.69% | 4,404,071 |
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
